Design and synthesis of anticancer agents to target abnormal metabolism and glycolysis of cancer cells and epigenetic enzymes. Development of synthetic methodologies to construct drug-like molecules for anticancer drug screening.

1. 1995-1999: B.Sc. in chemistry, Department of Chemistry, Jilin University 

2. 1999-2004: PhD. in organic chemistry, working on the total synthesis of cyclomarin C, Shanghai Institute of Organic Chemistry, Chinese Academy of Sciences.

1.     Zhu D, Wu Y, Wu B, Luo B, Ganesan A, Pi R, WuF-H, Huang P, Wen S*. Three-component Pd/Cu-catalyzed cascade reactions ofcyclic iodoniums, alkynes, and boronic acids: an approach tomethylidenefluorenes. Organic Letters 2014, 16, 2350-2353 (IF 6.32)

2.     Li M, Luo B, Liu Q, Hu Y, Ganesan A, Huang P, Wen S*. Synthesis of N-acyl-N,O-acetalsMediated by Titanium Ethoxide. Org. Lett. 2014, 16, 10-13. (IF 6.32)

3.     Chen M, Liu Q, Liu A,Tan M, Xie Z, Uri A, Chen Z, Huang G, Sun Y, Ge H, Liu P, Li M, Li X, Wen S*, Pi R* Simply combiningfasudil and lipoic acid in a novel multitargeted chemical entity potentiallyuseful in central nervous system disorders. RSCAdvances, 2014, accepted. (IF 3.7)

4.     Mageed SN, Cunningham F, Hung AW, SilvestreHL, Wen S, Blundell TL, AbellC, McConkey GA.Pantothenicacid biosynthesis in the parasite Toxoplasma gondii: a target for chemotherapy.  AntimicrobAgents Chemother. 2014 Jul21. pii: AAC.02640-14. [Epub ahead of print] (IF 4.45)

5.     Chen M, Tan M, Jing M, Liu A, Liu Q, Wen S, Chen Z, Chao X, He X,Ramassamy C, Gao Y, Pi R. Berberine protects homocysteic acid-induced HT-22 celldeath: involvement of Akt pathway. MetabBrain Dis. 2014 Jul23. [Epub ahead of print] (IF 2.40)

6.     Wang L, Wang R, Jin M, Huang Y, Liu A, Qin J,Chen M, Wen S, Pi R, Shen W. Carvedilol Attenuates6-Hydroxydopamine-Induced Cell Death in PC12 Cells: Involvement of Akt andNrf2/ARE Pathways. Neurochem Res. 2014 Jun 21. [Epubahead of print](IF 2.55)

7.      Wen, S., Zhu, D.,Huang, P. Targeting Cancer CellMitochondria as a Therapeutic Approach, FutureMed. Chem., 2013, 5(1):53-67. (IF 4.0)

8.      Zhu D, LiuQ, Luo B, Chen M, Pi R, Huang P, WenS*. Synthesis of Carbazoles via One-Pot Copper-Catalyzed Amine Insertion into CyclicDiphenyleneiodoniums as a Strategy to Generate a Drug-Like Chemical Library. Adv. Synth. Catal. 2013, 355, 2172-2178(IF 5.54)

9.      Zhu D, Chen M, Li M, Luo B, Zhao Y, Huang P, XueF, Rapposelli A, Pi R, WenS*. Discovery of novel N-substituted carbazoles as neuroprotectiveagents with potent anti-oxidative activity. Eur.J. Med. Chem. 2013, 68, 81-88. (IF 3.50)

10.   Guan R, Xu X, Chen M, Hu H, Ge H, Wen S*, Zhou S, Pi R. Advancesin the studies of roles of Rho/Rho-kinase in diseases and the development ofits inhibitors. Eur. J. Med. Chem. 2013, 70, 613-622. (IF 3.50)

11.   Zhou B, Zuo Y, Li B, Wang H, Liu H, Wang X, Qiu X, Hu Y, WenS, Du J, Bu X. Deubiquitinase Inhibition of 19S RegulatoryParticles by 4-Arylidene Curcumin Analogue AC17 Causes NF-κB Inhibition and p53Reactivation in Human Lung Cancer Cells. Mol Cancer Ther. 2013, 12(8):1381-92.(IF 5.23)

12.   Li X, Lu W, Hu Y, Wen S, Qian C, Wu W, Huang P*.Effective inhibition of nasopharyngeal carcinoma in vitro and in vivo bytargeting glycolysis with oxamate. Int. J. Oncol. 2013, 43(5): 1710-1718. (IF 2.40)

13.    Abrahams GL, Kumar A, Savvi S, Hung AW, Wen S, Abell C, Barry CE 3rd,Sherman DR, Boshoff HI, Mizrahi V. Pathway-Selective Sensitization of Mycobacteriumtuberculosis for Target-Based Whole-Cell Screening. Chem Biol. 2012, 27, 19(7), 844-54. (IF 6.59)

14.   Tiffon C., Adams J., van der Fits L., WenS, Townsend P., Ganesan A., Hodges E., Vermeer M., Packham G. Thehistone deacetylase inhibitors Vorinostat and Istodax downmodulate IL10expression in cutaneous T-cell lymphoma cells British Journal ofPharmacology, 2011, 162，1590-1602. (IF 4.99)

15.   Hung A.W., Silvestre H.L., Wen S,Ciulli A., Blundell T.L., Abell C. Application of fragment growing and fragmentlinking to the discovery of novel inhibitors of Mycobacterium tuberculosispantothenate synthetase Angew. Chem. Int. Ed. 2009, 48, 8452-8456. (IF11.34)

16.   Heikkila T.J., Surade S.,Silvestre H.L., Dias M.V.B., Ciulli A., Bromfield K., Scott D., Howard N., WenS, Wei A.H., Osborne D., Abell C. Blundell T.L. Fragment-based drugdiscovery in academia: experiences from a tuberculosis programme NATOSecurity through Science Series C: Environmental Security, 2009, 21-36.

17.    Wen S, Packham, G.,Ganesan, A. Macrolactamization versus Macrolactonization: Total Synthesis ofFK228, the Depsipeptide Histone Deacetylase Inhibitor J Org Chem, 2008, 73, 9353-9361. (IF 4.64)

18.    Wen S, Carey K., Nakao Y.,Fusetani N., Packham G., Ganesan A. Total Synthesis of Azumamide A andAzumamide E, Evaluation as Histone Deactylase Inhibitors, and Design of a MorePotent Analogue Organic Letters 2007,9 (6), 1105-1108. (IF6.32)

19.   Yurek-George A., Cecil A., Mo A.H.K., WenS, Rogers H., Maeda S., Yoshida M., Packham G., Ganesan A., The FirstBiologically Active Synthetic Analogues of FK228, the Depsipeptide HistoneDeacetylase Inhibitor, J. Med. Chem., 2007; 50(23); 5720-5726. (IF5.48)

20.    Wen, SJ, Hu, T.-S., Yao,Z.-J. Macrocylization Studies and Total Synthesis of Cyclomarin C, anAnti-inflammatory Marine Cyclopeptide, Tetrahedron, 2005, 61 (21), 4931-4938. (IF2.82)

21.    Wen, SJ, Yao, Z.-J. TotalSynthesis of Cyclomarin C. Organic Letters 2004, 6 (16) 2721-2724. (IF6.32)

22.    Wen, SJ, Zhang HY, Yao Z.-J. Synthesis of a fully protected (2S, 3R)-N-(1 ',1 '-dimethyl-2'-propenyl)-3-hydroxytrypto- phan from tryptophan. TetrahedronLett.2002, 43, 5291-5294. (IF2.39)

 

Last updated on: August, 2014